价值导向合同下的归因人数停滞，总是四件事之一，而其中只有一件通常在本季度对你可用。 医疗服务提供商在此面临特定困境——已在38,000人身上承担了下行风险，却缺乏定价所需的分次成本数据。在定价之前，分次成本会因无人能归因的原因持续变动，而关于每月新客户的争论仍将是意见问题。
价值导向合同下的归因人数停滞，总是四件事之一，而其中只有一件通常在本季度对你可用。 医疗服务提供商在此面临特定困境——已在38,000人身上承担了下行风险，却缺乏定价所需的分次成本数据。在定价之前，分次成本会因无人能归因的原因持续变动，而关于每月新客户的争论仍将是意见问题。
价值导向合同下的归因人数只以四种方式变动：更多合同带来新归因人数、通过 payer mix 或降低分次成本提高每位提供商的贡献、更好留存现有合同，或新服务线。这个清单已知。几乎没人做的是找出哪根杠杆未被堵住，因为其中三根通常已被堵住。
停滞具有诊断意义。如果归因人数稳定且每位提供商贡献持平，你就面临分次成本或 payer mix 问题。如果新归因人数下降而收入维持，你正靠即将耗尽的基数生存。如果两者均持平且留存强劲，你已饱和能管理的合同，下一步是不同 payer 细分，而非在此细分内加把劲。
停滞持续的原因在于，回应通常是“管理更多人数”——把更多活动投向已不再响应的杠杆。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 价值导向合同下的归因人数与去年相差仅几个百分点，而分次成本未改善
✓ 每位提供商的面板规模稳定且贡献不变
✓ 所有提出的修复都是“更多归因人数”的变体
通常会让情况更糟的做法。 在已停止响应的合同上增加管理更多归因人数的产能，这把增长问题转化为成本问题。
It is for you if you run or finance a healthcare provider and revenue is within a few percent of last year while headcount and cost have grown. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Sell coordinated care bundles directly to self-insured employers using existing clinic density and ASC capacity.
The leak it closes. Bypasses commercial payer take-rate (estimated 15–20% of premium) and prior-authorization friction, reducing denial leakage on these lives to near zero
The assumption it rests on. At least two of the five largest self-insured employers in the two metros will sign a 3-year direct contract within 18 months — the engine put the probability at 0.7.
| Investment required | $2M over 36 months ($800K Year 1, $700K Year 2, $500K Year 3) |
| Expected return | 6.0–9.0× on $2M investment |
| Revenue, year 1 | $0 incremental (pilot setup and first contract negotiations) |
| Revenue, year 2 | $4–6M incremental (2–3 employer contracts, 4,000–6,000 covered lives) |
| Revenue, year 3 | $12–18M incremental (5 employer contracts, 10,000–15,000 covered lives) |
| Exit criteria | Terminate pilot and redeploy 4 FTEs if fewer than 2 employer contracts signed by Month 18 OR if operating margin on employer channel falls below 6% for two consecutive quarters |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长策略, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
最初通常都不是——是细分问题。你学会销售的细分已耗尽，下一个细分因不同理由购买。针对旧细分的营销和产品改变只会让停滞更昂贵，而非缩短它。
连续两个季度，调整季节性后。一个季度持平在多数业务中是噪音。两个季度是模式，而等待第三个季度的代价是把一年 runway 花在已停止工作的杠杆上。
仅削减附着于已停止响应杠杆的成本。均匀削减会移除你仍需用于开放杠杆的产能，这通常是停滞转为下滑的方式。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית